Regeneron Pharmaceuticals, Inc. $REGN Stock: Jefferies Financial Group Inc. Grows Stake

Jefferies Financial Group Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,300 shares of the biopharmaceutical company’s stock after buying an additional 560 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $15,393,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Machina Capital S.A.S. grew its stake in shares of Regeneron Pharmaceuticals by 7.0% in the third quarter. Machina Capital S.A.S. now owns 4,094 shares of the biopharmaceutical company’s stock valued at $3,104,000 after acquiring an additional 267 shares in the last quarter. Illinois Municipal Retirement Fund increased its position in Regeneron Pharmaceuticals by 3.9% during the third quarter. Illinois Municipal Retirement Fund now owns 31,884 shares of the biopharmaceutical company’s stock worth $24,177,000 after acquiring an additional 1,209 shares during the period. Lido Advisors LLC increased its position in Regeneron Pharmaceuticals by 26.0% during the third quarter. Lido Advisors LLC now owns 14,677 shares of the biopharmaceutical company’s stock worth $11,129,000 after acquiring an additional 3,030 shares during the period. Cornerstone Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $254,000. Finally, Csenge Advisory Group acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $237,000. Institutional investors own 83.31% of the company’s stock.

Key Regeneron Pharmaceuticals News

These are some of the REGN news items that stood out recently:

• Positive Sentiment: Regeneron collaborator Alnylam reported first-in-human results for CIDEBsiRNA in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD). A single dose rapidly normalized liver fat and improved markers of liver injury, providing encouraging early evidence for a potential treatment opportunity. Article: Alnylam collaborator Regeneron advances CIDEBsiRNA with promising first-in-human results
• Positive Sentiment: Soleo Health was selected as a specialty-pharmacy partner for Pasatru (garetosmab), Regeneron’s recently approved treatment for adults with the rare disorder fibrodysplasia ossificans progressiva. The partnership may support the drug’s distribution and patient access, although no sales impact was specified. Article: Soleo Health selected as a specialty pharmacy partner for Pasatru
• Neutral Sentiment: A Zacks article characterized REGN as a long-term value stock, but the summary provided no new company-specific developments or valuation details that would clearly explain near-term trading. Article: Why Regeneron is a top value stock for the long term

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on REGN. Robert W. Baird boosted their price objective on shares of Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the company a “neutral” rating in a report on Monday, November 2nd. Jefferies Financial Group increased their target price on shares of Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Sanford C. Bernstein upped their target price on Regeneron Pharmaceuticals from $756.00 to $812.00 and gave the company a “market perform” rating in a research report on Monday, November 2nd. BMO Capital Markets increased their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Finally, Argus raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 target price on the stock in a report on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $898.97.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $959.41 on Thursday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $991.73. The company has a quick ratio of 2.89, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. The stock’s 50-day simple moving average is $811.95 and its 200 day simple moving average is $745.49. The firm has a market capitalization of $99.25 billion, a PE ratio of 21.18, a price-to-earnings-growth ratio of 1.21 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping the consensus estimate of $16.51 by $3.56. The firm had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business’s quarterly revenue was up 36.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $11.83 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.30%.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Joseph J. Larosa sold 4,466 shares of the stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $965.49, for a total value of $4,311,878.34. Following the completion of the transaction, the executive vice president owned 38,906 shares of the company’s stock, valued at $37,563,353.94. This represents a 10.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $900.00, for a total transaction of $360,000.00. Following the completion of the transaction, the director directly owned 603 shares of the company’s stock, valued at approximately $542,700. The trade was a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 27,028 shares of company stock worth $25,025,950 in the last ninety days. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.